Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01947491 · ClinicalTrials.gov registry record · Phase 3
A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis
A Phase 3 study of Psoriasis, sponsored by Primus Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 394
- Enrollment target
- 20
- Study locations
NCT01947491: Completed Phase 3 study of Psoriasis, sponsored by Primus Pharmaceuticals.
NCT01947491 is a Phase 3 study of Psoriasis that has completed, run by Primus Pharmaceuticals. The registered enrollment target is 394 participants, below the 486-participant average among 125 other Psoriasis trials with a reported enrollment target (19% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01947491, a Phase 3 study of Psoriasis, has completed, sponsored by Primus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 394 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objectives of this study are to compare the safety of DFD01 Spray to Comp01 Lotion for topical treatment of moderate plaque psoriasis and to compare the efficacy of DFD01 Spray to Placebo Spray for topical treatment of moderate plaque psoriasis after 28 days of treatment.
Primary Outcome
IGA of clear or almost clear
Conditions Studied
Interventions
- DRUG Vehicle Lotion
- DRUG DFD01 Spray
- DRUG Comp01 Lotion
- DRUG Vehicle Spray
Study Locations (20)
California
- California Dermatology and Clinical Research Institute - Encinitas
- Encino Research Center - Encino
- Center for Dematology Clinical Research, Inc. - Fremont
- Skin Surgery Medical Group, Inc. - San Diego
- Redwood Dermatology Research - Santa Rosa
Colorado
- Cherry Creek Research, Inc. - Denver
- Colorado Medical Research Center Inc. - Denver
Florida
- Florida Academic Center Research and Education - Miami
- International Dermatology Research Inc. - Miami
Indiana
- The Indiana Clinical Trials Center - Plainfield
- South Bend Clinic, LLP - South Bend
Alabama
- Horizon Research Group, Inc. - Mobile
Arkansas
- Burke Pharmaceutical Research - Hot Springs
Connecticut
- The Savin Center, PC - New Haven
Kansas
- Compliant Clinical Research Inc. - Olathe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 394 participants |
| Start Date | 2013-11 |
| Est. Completion | 2015-01 |
| Phase | Phase 3 |
What the finished NCT01947491 record still lists
NCT01947491 is an interventional study that assigns participants to a tested intervention. The registered 394 participants enrollment target is mid-sized for trials with a published cap, below the 486-participant average among 125 other Psoriasis trials with a reported enrollment target (19% lower).
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 4 interventions - of which Vehicle Lotion is the first listed.
NCT01947491 names 20 study sites across 13 states, led by California, Colorado, Florida.
Frequently Asked Questions
What is clinical trial NCT01947491 about?
NCT01947491 is a clinical study titled "A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis". The objectives of this study are to compare the safety of DFD01 Spray to Comp01 Lotion for topical treatment of moderate plaque psoriasis and to compare the efficacy of DFD01 Spray to Placebo Spray for topical treatment of moderate plaque psoriasis after 28 days of treatment.
What is the current status of trial NCT01947491?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 394 participants. The study started on 2013-11. Estimated completion is 2015-01.
What conditions does trial NCT01947491 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT01947491?
The interventions under investigation include: Vehicle Lotion (DRUG), DFD01 Spray (DRUG), Comp01 Lotion (DRUG), Vehicle Spray (DRUG).
Who is sponsoring clinical trial NCT01947491?
This trial is sponsored by Primus Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01947491 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01947491's enrollment target sits among peer trials
394 23rd of 125 higher than 103 of 125 other Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977
ACTIVE NOT RECRUITING · Phase 3
-
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06657924 · 394 participants · Phase 2
Preoperative Tranexamic Acid (TXA) to Prevent Bleeding in Patients Undergoing Major Colorectal Surgery
- NCT07225660 · 394 participants · NA
Hormonal Optimization: Late vs. Immediate Start After Discontinuation of Oral Contraceptives in Assisted Reproductive technologY (HOLIDAY)
- NCT07207369 · 395 participants · Phase 3
A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars
- NCT05640999 · 393 participants · Phase 2
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia